QC
VRTX icon

Quent Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Quent Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$251K Buy
563
+6
+1% +$2.8K 0.02% 327
2025
Q4 		$253K Buy
557
+56
+11% +$24.1K 0.02% 339
2025
Q3 		$196K Buy
501
+26
+5% +$10.9K 0.02% 284
2025
Q2 		$211K Sell
475
-38
-7% -$17.5K 0.02% 265
2025
Q1 		$249K Buy
513
+22
+4% +$10.3K 0.03% 221
2024
Q4 		$198K Sell
491
-49
-9% -$22.7K 0.02% 264
2024
Q3 		$251K Buy
540
+117
+28% +$56.2K 0.03% 294
2024
Q2 		$198K Buy
423
+24
+6% +$10.4K 0.02% 316
2024
Q1 		$167K Buy
399
+99
+33% +$41.9K 0.02% 368
2023
Q4 		$122K Buy
300
+118
+65% +$43.6K 0.02% 401
2023
Q3 		$63.3K Buy
182
+96
+112% +$33.6K 0.01% 529
2023
Q2 		$30.3K Buy
86
+41
+91% +$13.8K ﹤0.01% 705
2023
Q1 		$14.2K Sell
45
-16
-26% -$4.8K ﹤0.01% 848
2022
Q4 		$17.6K Buy
61
+12
+24% +$3.66K ﹤0.01% 785
2022
Q3 		$14K Buy
49
+5
+11% +$1.44K ﹤0.01% 811
2022
Q2 		$12K Buy
44
+8
+22% +$2.14K ﹤0.01% 800
2022
Q1 		$9K Sell
36
-56
-61% -$13.3K ﹤0.01% 937
2021
Q4 		$20K Buy
+92
New +$17.9K ﹤0.01% 721

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Quent Capital's VRTX Position: Q1 2026 in Review

Quent Capital increased its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q1 2026, buying an estimated $2.8K and bringing the position to 563 shares worth $251K. The position accounts for 0.02% of the portfolio, ranked #327.

Quent Capital first reported a position in VRTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $253K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Quent Capital held 563 shares of Vertex Pharmaceuticals worth $251K as of Q1 2026.
  • Quent Capital bought 6 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.8K.
  • Vertex Pharmaceuticals made up 0.02% of Quent Capital's portfolio in Q1 2026, its #327 holding.
  • Quent Capital first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Quent Capital's Vertex Pharmaceuticals position peaked at $253K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Quent Capital's 13F filing for Q1 2026, filed 28 Apr 2026.